Syed Husain, MD
Nephrology · New York, NYNPI 1952696221
Payments from drug & device makers
Across 18 payments — averaging $486.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$8K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$250
- Fresenius USA Marketing, Inc.$249
- Calliditas Therapeutics US Inc.$161
- Biotronik Inc.$135
- Sanofi-aventis U.S. LLC$131
- plus $245 from 2 others
What the payments were for
- Consulting fees$6,50074%
- Speaking & faculty fees$2493%
- Travel & lodging$7579%
- Food & beverage$1,11213%
- Education$1352%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 6 | $7,583 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $250 |
| Fresenius USA Marketing, Inc. | 1 | $249 |
| Calliditas Therapeutics US Inc. | 2 | $161 |
| Biotronik Inc. | 4 | $135 |
| Sanofi-aventis U.S. LLC | 1 | $131 |
| Sanofi | 1 | $127 |
| Otsuka America Pharmaceutical, Inc. | 1 | $118 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fabhalta$7,555
- TARPEYO$145
- THYMOGLOBULIN$131
- FABRAZYME$127
- JYNARQUE$118
How this compares
$8,753 in reported general payments places this provider in the 80th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Entecavir | 14 | $2,346 |
| Cinacalcet Hcl | 11 | $409 |
| Calcitriol | 11 | $178 |
| Pantoprazole Sodium | 12 | $100 |
| Amlodipine Besylate | 12 | $99 |
| Metoprolol Tartrate | 18 | $69 |
| Losartan Potassium | 17 | $60 |
| Carvedilol | 12 | $47 |
| Gabapentin | 12 | $22 |
| Amoxicillin | 14 | $9 |
Paid to pharmacies, not to this prescriber.
Other nephrology in New York
- Joji TokitaNew York$8.4M
- Krzysztof KirylukNew York$6.7M
- David BernardNew York$6M
- Andrew BombackNew York$3.4M
- Pietro CanettaNew York$3.2M
- Gerald AppelNew York$1.5M
- David CharytanNew York$1.3M
- Kirk CampbellNew York$1.1M
- Jai RadhakrishnanNew York$995K
- Girish NadkarniNew York$978K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.